HC Wainwright & Co. Maintains Buy on Protalix BioTherapeutics, Raises Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju maintains a 'Buy' rating on Protalix BioTherapeutics (AMEX:PLX) and raises the price target from $7 to $10.
October 31, 2023 | 11:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Protalix BioTherapeutics' price target has been raised from $7 to $10 by HC Wainwright & Co. The firm maintains a 'Buy' rating on the stock.
The news of a price target increase and maintained 'Buy' rating by a reputable firm like HC Wainwright & Co. is likely to instill confidence in investors and could lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100